Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.5K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.5K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

1.5K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.5K
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

259
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
259
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

6.6K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
6.6K
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

216
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
216

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Cross-Sectional Street Survey Examining a Preference for Truth-Telling in Serious Illness and End-of-Life in Maputo City Province.

Journal of palliative medicine·2026
Same author

Defining and Managing End-of-Life Respiratory Changes in Adult Home Hospice Patients: A Systematic Review.

Journal of palliative medicine·2025
Same author

Prevalence and Factors Associated With Receiving a Prescription for Antithrombotic Therapy on Hospice Admission.

Journal of the American Geriatrics Society·2025
Same author

Virtual reality for outpatient management of cancer pain: a pilot dosing study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same author

Protein sequence modelling with Bayesian flow networks.

Nature communications·2025
Same author

Implementation of a Standardized Palliative Care Pharmacist Deprescribing Assessment.

Journal of palliative medicine·2025

Related Experiment Video

Updated: Apr 4, 2026

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
10:13

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Published on: November 8, 2024

3.0K

Variability in Opioid Equivalence Calculations.

Amanda Rennick1, Timothy Atkinson2, Nina M Cimino3

  • 1Clinical Specialist; Stratton VA Medical Center, Albany, New York, USA.

Pain Medicine (Malden, Mass.)
|September 10, 2015
PubMed
Summary
This summary is machine-generated.

Opioid conversion estimates show significant variability among healthcare professionals, leading to potential risks for patients. No single method ensures accurate and consistent opioid conversions to morphine equivalents.

Keywords:
ConversionEquivalenceOpioidVariability

More Related Videos

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.8K
Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

3.4K

Related Experiment Videos

Last Updated: Apr 4, 2026

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
10:13

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Published on: November 8, 2024

3.0K
Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.8K
Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

3.4K

Area of Science:

  • Pain Management
  • Pharmacology
  • Clinical Pharmacy

Background:

  • Equianalgesic conversion is crucial for opioid therapy adjustments.
  • Variability in conversion methods poses risks of undertreated pain and adverse events.
  • A standardized approach to opioid conversion is lacking.

Purpose of the Study:

  • To compare equianalgesic conversion estimates for common opioids among nurse practitioners, pharmacists, and physicians.
  • To identify variations in opioid conversion practices across different healthcare professional groups.

Main Methods:

  • A survey was distributed online to collect data on opioid conversions.
  • Participants provided estimated morphine equivalents (MEQs) for specific opioid doses.
  • Descriptive and inferential statistical analyses were used to compare conversion estimates.

Main Results:

  • Significant variation in mean MEQ doses was observed, especially for fentanyl and methadone.
  • Median MEQ doses for opioid conversions were consistent across professional groups.
  • Large standard deviations indicated substantial variability within each profession.

Conclusions:

  • No universal method exists for accurate and consistent opioid conversion.
  • Significant variability in opioid conversion estimates persists among clinicians.
  • Patient safety may be compromised due to inconsistent opioid conversion practices.